This is a multicenter, open-label trial to evaluate the efficacy and safety of AXS-07 in subjects with migraine attacks and prior inadequate response to oral CGRP inhibitors.
Eligible subjects will receive open-label AXS-07 for up to 8 weeks for at-home treatment of their next 4 migraine attacks.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
100
AXS-07 tablets, taken orally for the acute treatment of migraine
Percentage of subjects with headache pain relief
Absence of headache pain and without the use of rescue medication.
Time frame: Hour 2 following dose administration
Percentage of subjects with absence of the Most Bothersome Symptom
Absence of the most bothersome symptom, defined at the onset of migraine.
Time frame: Hour 2 following dose administration
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Clinical Research Site
Colton, California, United States
Clinical Research Site
Fullerton, California, United States
Clinical Research Site
La Jolla, California, United States
Clinical Research Site
Los Angeles, California, United States
Clinical Research Site
Sherman Oaks, California, United States
Clinical Research Site
Stamford, Connecticut, United States
Clinical Research Site
DeLand, Florida, United States
Clinical Research Site
Hallandale, Florida, United States
Clinical Research Site
Hollywood, Florida, United States
Clinical Research Site
Miami, Florida, United States
...and 21 more locations